The unpluggable in pursuit of the undruggable: Tackling the dark matter of the cancer therapeutics universe

Frontiers in Oncology

Volumn 3 DEC, Issue , 2013, Pages

  Epstein, Richard J ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Apoptosis; Carcinogenesis; Drug development; Genetic instability; Tumor suppressor genes

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FLUOROPYRIMIDINE; G PROTEIN COUPLED RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; PROTEIN MLH1; PROTEIN P53; PROTEINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER PROGNOSIS; CANCER THERAPY; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL (TOPIC); HUMAN; MICROSATELLITE INSTABILITY; MUTATION; NONHUMAN; NOTE; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR SUPPRESSOR GENE;

EID: 84892384582     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00304     Document Type: Note

References (85)

1. Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res (2010) 16(24):5972-80. doi:10.1158/1078-0432.CCR-10-1277.
2. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature (1997) 386(6627):761-67.
3. Zhao Y, Epstein RJ. Unexpected functional similarities between gatekeeper tumour suppressor genes and proto-oncogenes revealed by systems biology. J Hum Genet (2011) 56(5):369-76. doi:10.1038/jhg.2011.21.
4. Li GM. DNA mismatch repair and cancer. Front Biosci (2003) 8:d997-1017. doi:10.2741/1121.
5. van Heemst D, den Reijer PM, Westendorp RG. Ageing or cancer: a review on the role of caretakers and gatekeepers. Eur J Cancer (2007) 43(15):2144-52. doi:10.1016/j.ejca.2007.07.011.
6. Corcos D. Unbalanced replication as a major source of genetic instability in cancer cells. Am J Blood Res (2012) 2(3):160-9.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013.
8. Huang GC, Hobbs S, Walton M, Epstein RJ. Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br J Cancer (2002) 86(7):1104-9. doi:10.1038/sj.bjc.6600219.
9. Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J. Abnormal cell cycle regulation in malignancy. Am J Clin Pathol (1999) 112(1 Suppl 1):S40-52.
10. Zhao Y, Epstein RJ. Programmed genetic instability: a tumor-permissive mechanism for maintaining the evolvability of higher species through methylation-dependent mutation of DNA repair genes in the male germ line. Mol Biol Evol (2008) 25(8):1737-49. doi:10.1093/molbev/msn126.
11. Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer (2012) 19(6):R225-41. doi:10.1530/ERC-12-0203.
12. Schmitt M, Walker MP, Richards RG, Bocchinfuso WP, Fukuda T, Medina D, et al. Expression of heregulin by mouse mammary tumor cells: role in activation of ErbB receptors. Mol Carcinog (2006) 45(7):490-505. doi:10.1002/mc.20180.
13. Way TD, Lin JK. Role of HER2/HER3 co-receptor in breast carcinogenesis. Future Oncol (2005) 1(6):841-9. doi:10.2217/14796694.1.6.841.
14. Connolly K, Brungs D, Szeto E, Epstein RJ. Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma. Curr Oncol (in press).
15. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 483(7387):100-3. doi:10.1038/nature10868.
16. Epstein RJ. Growth of the Asian health-care market: global implications for the pharmaceutical industry. Nat Rev Drug Discov (2007) 6(10):785-92. doi:10.1038/nrd2360.
17. Epstein RJ. Has discovery-based cancer research been a bust? Clin Transl Oncol (2013) 15(11):865-70. doi:10.1007/s12094-013-1071-8.
18. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2012) 30(2):134-41. doi:10.1200/JCO.2011.35.5040.
19. Simon R. Translational research in oncology: key bottlenecks and new paradigms. Expert Rev Mol Med (2010) 12:e32. doi:10.1017/S1462399410001638.
20. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin (2009) 59(2):111-37. doi:10.3322/caac.20003.
21. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2012) 72(2):527-36. doi:10.1158/0008-5472.CAN-11-3004.
22. Epstein RJ, Leung TW. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res (2007) 13(1):11-7. doi:10.1158/1078-0432.CCR-06-1619.
23. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science (2013) 339(6127):1546-58. doi:10.1126/science.1235122.
24. Connolly K, Manders P, Earls P, Epstein RJ. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. Cancer Treat Rev (2014) 40(2):205-14. doi:10.1016/j.ctrv.2013.08.005.
25. Lynch HT, Lynch PM. Colorectal cancer: update on the clinical management of Lynch syndrome. Nat Rev Gastroenterol Hepatol (2013) 10(6):323-4. doi:10.1038/nrgastro.2013.70.
26. Stein A, Hiemer S, Schmoll HJ. Adjuvant therapy for early colon cancer: current status. Drugs (2011) 71(17):2257-75. doi:10.2165/11594490-000000000-00000.
27. Xue C, Plieth D, Venkov C, Xu C, Neilson EG. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res (2003) 63(12):3386-94.
28. van Boxtel R, Kuiper RV, Toonen PW, van Heesch S, Hermsen R, de Bruin A, et al. Homozygous and heterozygous p53 knockout rats develop metastasizing sarcomas with high frequency. Am J Pathol (2011) 179(4):1616-22. doi:10.1016/j.ajpath.2011.06.036.
29. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 28(20):3219-26. doi:10.1200/JCO.2009.27.1825.
30. Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, et al. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst (2013) 105(13):989-92. doi:10.1093/jnci/djt140.
31. Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet (2010) 47(11):771-4. doi:10.1136/jmg.2010.078113.
32. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A (2003) 100(15):8933-8. doi:10.1073/pnas.1537685100.
33. Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene (2012) 31(6):706-15. doi:10.1038/onc.2011.275.
34. Hellyer NJ, Kim MS, Koland JG. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem (2001) 276(45):42153-61. doi:10.1074/jbc.M102079200.
35. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol (1999) 26(4 Suppl 12): 89-95.
36. Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat (2010) 119(1):127-36. doi:10.1007/s10549-009-0498-7.
37. Nishimura R, Okumura Y, Arima N. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Breast Cancer (2008) 15(1):57-64. doi:10.1007/s12282-007-0014-z.
38. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol (2010) 177(4):1647-56. doi:10.2353/ajpath.2010.090885.
39. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol (2011) 29(2):166-73. doi:10.1200/JCO.2009.27.7814.
40. Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res (2012) 18(24):6784-91. doi:10.1158/1078-0432.CCR-12-1785.
41. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 29(23):3126-32. doi:10.1200/JCO.2010.32.2321.
42. Lim YP, Diong LS, Qi R, Druker BJ, Epstein RJ. Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells. Mol Cancer Ther (2003) 2(12):1369-77.
43. Haverty PM, Fridlyand J, Li L, Getz G, Beroukhim R, Lohr S, et al. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer (2008) 47(6):530-42. doi:10.1002/gcc.20558.
44. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2013) 63(5):920-6. doi:10.1016/j.eururo.2012.08.053.
45. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer (2013) 108(10):2153-63. doi:10.1038/bjc.2013.212.
46. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature (2013) 497(7447):67-73. doi:10.1038/nature12113.
47. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat (2003) 21(3):301-6. doi:10.1002/humu.10173.
48. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 105(15):1151-6. doi:10.1093/jnci/djt173.
49. Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol (2012) 8(6):651-7. doi:10.2217/fon.12.49.
50. Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bartschi D, Droge C, et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol (2013) 64(1):150-8. doi:10.1016/j.eururo.2013.03.040.
51. Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw (2013) 11(6):670-8.
52. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res (2012) 18(6):1777-89. doi:10.1158/1078-0432.CCR-11-2123.
53. Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One (2013) 8(1):e53292. doi:10.1371/journal.pone.0053292.
54. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J (2009) 15(2):110-3. doi:10.1097/PPO.0b013e31819e3202.
55. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene (2011) 30(29):3222-33. doi:10.1038/onc.2011.42.
56. Martin SA, Hewish M, Lord CJ, Ashworth A. Genomic instability and the selection of treatments for cancer. J Pathol (2010) 220(2):281-9. doi:10.1002/path.2631.
57. Moller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, et al. Genetic epidemiology of BRCA mutations-family history detects less than 50% of the mutation carriers. Eur J Cancer (2007) 43(11):1713-7. doi:10.1016/j.ejca.2007.04.023.
58. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, et al. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res (2006) 8(2):R15. doi:10.1186/bcr1570.
59. Oliver A, Mena A. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin Microbiol Infect (2010) 16(7):798-808. doi:10.1111/j.1469-0691.2010.03250.x.
60. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434(7035):913-7. doi:10.1038/nature03443.
61. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 105(44):17079-84. doi:10.1073/pnas.0806092105.
62. Kyle S, Thomas HD, Mitchell J, Curtin NJ. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer. Br J Radiol (2008) 81(Spec No 1):S6-11. doi:10.1259/bjr/99111297.
63. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 10(8):1192-9. doi:10.4161/cc.10.8.15273.
64. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol (2011) 5(4):387-93. doi:10.1016/j.molonc.2011.07.001.
65. De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol (2013) 3:228. doi:10.3389/fonc.2013.00228.
66. Deng CX, Scott F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene (2000) 19(8):1059-64. doi:10.1038/sj.onc.1203269.
67. Wang Z, Wang F, Tang T, Guo C. The role of PARP1 in the DNA damage response and its application in tumor therapy. Front Med (2012) 6(2):156-64. doi:10.1007/s11684-012-0197-3.
68. Chiarugi A. A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol Sci (2012) 33(1):42-8. doi:10.1016/j.tips.2011.10.001.
69. Michalak EM, Jonkers J. Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer. J Mammary Gland Biol Neoplasia (2011) 16(1):41-50. doi:10.1007/s10911-011-9199-z.
70. Montoni A, Robu M, Pouliot E, Shah GM. Resistance to PARP-inhibitors in cancer therapy. Front Pharmacol (2013) 4:18. doi:10.3389/fphar.2013.00018.
71. Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell (2011) 20(6):797-809. doi:10.1016/j.ccr.2011.11.014.
72. Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer (2013) 108(10):2172-7. doi:10.1038/bjc.2013.144.
73. Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist (2013) 18(8):909-16. doi:10.1634/theoncologist.2013-0039.
74. Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol (2013) 18(19):3360-9. doi:10.1016/j.critrevonc.2013.08.002.
75. Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist (2012) 17(7):956-62. doi:10.1634/theoncologist.2012-0028.
76. Demicheli R, Pratesi G, Foroni R. The exponential-Gompertzian tumor growth model: data from six tumor cell lines in vitro and in vivo. Estimate of the transition point from exponential to Gompertzian growth and potential clinical implications. Tumori (1991) 77(3):189-95.
77. Mathers JC, Strathdee G, Relton CL. Induction of epigenetic alterations by dietary and other environmental factors. Adv Genet (2010) 71:3-39. doi:10.1016/B978-0-12-380864-6.00001-8.
78. Smithers DW. An attack on cytologism. Lancet (1962) 1(7228):493-9. doi:10.1016/S0140-6736(62)91475-7.
79. Merelli B, Massi D, Cattaneo L, Mandala M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol (2013). doi:10.1016/j.critrevonc.2013.08.002.
80. Campbell KL, Foster-Schubert KE, Makar KW, Kratz M, Hagman D, Schur EA, et al. Gene expression changes in adipose tissue with diet-and/or exercise-induced weight loss. Cancer Prev Res (2013) 6(3):217-31. doi:10.1158/1940-6207.CAPR-12-0212.
81. Boston EA, Gaffney EA. The influence of toxicity constraints in models of chemotherapeutic protocol escalation. Math Med Biol (2011) 28(4):357-84. doi:10.1093/imammb/dqr004.
82. Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer (2013) 132(1):236-45. doi:10.1002/ijc.27654.
83. Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer (2004) 4(11):901-9. doi:10.1038/nrc1473.
84. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 304(5670):554. doi:10.1126/science.1096502.
85. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417(6892):949-54. doi:10.1038/nature00766.